News | March 06, 2024
Bayer strengthens pharma portfolio with new cardiology drug acoramidis
Acquisition of exclusive commercialization rights for European markets
Acquisition of exclusive commercialization rights for European markets
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
Subscribe To Our Newsletter & Stay Updated
